Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD3 + anti-CD7 ricin A immunotoxins for steroid-refractory acute graft-versus-host disease
NL-OMON31737Phase 2Withdrawn
- Sponsor
- Thermo Fisher Scientific
- Start
- May 2008
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-CD3 ricin A immunotoxin and anti-CD7 ricin A immunotoxin in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Thermo Fisher Scientific. Primary endpoint: Acute graft-versus-host disease response rate on Day 28. Planned start May 2008; status: withdrawn.
02
Drugs
anti-CD3 ricin A immunotoxinanti-CD7 ricin A immunotoxin
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NL-OMON31737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31737.